Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effects of pharmacokinetic processes and varied dosing schedules on the dynamics of acquired resistance to erlotinib in EGFR-mutant lung cancer.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Oct 2012

Foo Jasmine, Chmielecki Juliann, Pao William, Michor Franziska

Abstract excerpt

INTRODUCTION: Erlotinib (Tarceva) is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, which effectively targets EGFR-mutant driven non-small-cell lung cancer. However, the evolution of acquired resistance because of a second-site mutation (T790M) within EGFR remains an obstac...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Dose-Response Relationship, Drug
Share to Drug Administration Schedule

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to Erlotinib Hydrochloride

Share to Models, Theoretical

Share to Protein Kinase Inhibitors

Share to Quinazolines

Share to Tissue Distribution

Source

Open in PubMed Open full text

Identifiers

PMID: 22982659
DOI: 10.1097/JTO.0b013e31826146ee
PMCID: PMC3693219

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-22982659-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 9 closest

Effects of pharmacokinetic processes and varied dosing schedules on the dynamics of acquired resistance to erlotinib in EGFR-mutant lung cancer.PMID 22982659Read ↗

Dose-Dependent Mutation Rates Determine Optimum Erlotinib Dosing Strategies for EGFR Mutant Non-Small Cell Lung Cancer Patients.Semantic proximity Read ↗

Quantitative modeling of tumor dynamics and development of drug resistance in non-small cell lung cancer patients treated with erlotinib.Semantic proximity Read ↗

Evolution of Resistance to Targeted Anti-Cancer Therapies during Continuous and Pulsed Administration StrategiesSemantic proximity Read ↗

Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling.Semantic proximity Read ↗

The Impact of Microenvironmental Heterogeneity on the Evolution of Drug Resistance in Cancer CellsSemantic proximity Read ↗

Interplay of mutations, alternate mechanisms, and treatment breaks in leukaemia: Understanding and implications studied with stochastic models.Semantic proximity Read ↗

Dosage strategies for delaying resistance emergence in heterogeneous tumors.Semantic proximity Read ↗

Anti-cancer treatment schedule optimization based on tumor dynamics modelling incorporating evolving resistance.Semantic proximity Read ↗

Modeling HIV dynamics and antiviral response with consideration of time-varying drug exposures, adherence and phenotypic sensitivity.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.